Peer-reviewed publication in “The Oncologist” is now available onlineInvestigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day ...
Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...
As the U.S. banking sector enters a new wave of consolidation, are institutions asking the right cybersecurity questions ...
MapLight Therapeutics, Inc. ("MapLight") (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 ...
Hong Kong, Shanghai Tuesday, January 6, 2026, 13:00 Hrs [IST] ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated the Phase III ...
Zacks Investment Research on MSN
GLUE stock up 45% on positive interim data on inflammation drug
Monte Rosa Therapeutics GLUE jumped 45.41% following positive interim data from a phase-I study evaluating its immunology and ...
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system ...
The bigger problem in your cookie dough, at least by volume, is actually the flour. Surprise! And while getting sick from raw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback